These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27503896)

  • 1. Specificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human Cells.
    Federspiel JD; Codreanu SG; Goyal S; Albertolle ME; Lowe E; Teague J; Wong H; Guengerich FP; Liebler DC
    Mol Cell Proteomics; 2016 Oct; 15(10):3233-3242. PubMed ID: 27503896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A6 Peptide-Tagged Core-Disulfide-Cross-Linked Micelles for Targeted Delivery of Proteasome Inhibitor Carfilzomib to Multiple Myeloma In Vivo.
    Zhang C; Wang X; Cheng R; Zhong Z
    Biomacromolecules; 2020 Jun; 21(6):2049-2059. PubMed ID: 32338875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.
    Ao L; Reichel D; Hu D; Jeong H; Kim KB; Bae Y; Lee W
    J Pharmacol Exp Ther; 2015 Nov; 355(2):168-73. PubMed ID: 26311812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib.
    Agbana P; Lee MJ; Rychahou P; Kim KB; Bae Y
    Pharm Res; 2020 Oct; 37(11):213. PubMed ID: 33025286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways.
    Allegra A; Speciale A; Molonia MS; Guglielmo L; Musolino C; Ferlazzo G; Costa G; Saija A; Cimino F
    Toxicol In Vitro; 2018 Mar; 47():186-194. PubMed ID: 29223572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
    Baker AF; Hanke NT; Sands BJ; Carbajal L; Anderl JL; Garland LL
    J Exp Clin Cancer Res; 2014 Dec; 33(1):111. PubMed ID: 25612802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth.
    Lee MJ; Miller Z; Park JE; Bhattarai D; Lee W; Kim KB
    Sci Rep; 2019 Mar; 9(1):4089. PubMed ID: 30858500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
    Lee MJ; Bhattarai D; Yoo J; Miller Z; Park JE; Lee S; Lee W; Driscoll JJ; Kim KB
    J Med Chem; 2019 May; 62(9):4444-4455. PubMed ID: 30964987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carfilzomib.
    Engelhardt M; Szymaniak-Vits M; Ajayi S; Dold SM; Müller SJ; Scheubeck S; Wäsch R
    Recent Results Cancer Res; 2018; 212():265-283. PubMed ID: 30069635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib.
    Efentakis P; Doerschmann H; Witzler C; Siemer S; Nikolaou PE; Kastritis E; Stauber R; Dimopoulos MA; Wenzel P; Andreadou I; Terpos E
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
    Guan S; Zhao Y; Lu J; Yu Y; Sun W; Mao X; Chen Z; Xu X; Pan J; Sun S; Yang J
    Oncotarget; 2016 Nov; 7(46):75914-75925. PubMed ID: 27713150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5.
    Han B; Yao W; Oh YT; Tong JS; Li S; Deng J; Yue P; Khuri FR; Sun SY
    Oncotarget; 2015 Jul; 6(19):17532-42. PubMed ID: 26009898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.
    Yang G; Gao M; Zhang Y; Kong Y; Gao L; Tao Y; Han Y; Wu H; Meng X; Xu H; Zhan F; Wu X; Shi J
    Oncotarget; 2015 Sep; 6(29):26982-94. PubMed ID: 26323098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation.
    Park JE; Park J; Jun Y; Oh Y; Ryoo G; Jeong YS; Gadalla HH; Min JS; Jo JH; Song MG; Kang KW; Bae SK; Yeo Y; Lee W
    J Control Release; 2019 May; 302():148-159. PubMed ID: 30954620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.
    Park JE; Chun SE; Reichel D; Min JS; Lee SC; Han S; Ryoo G; Oh Y; Park SH; Ryu HM; Kim KB; Lee HY; Bae SK; Bae Y; Lee W
    PLoS One; 2017; 12(3):e0173247. PubMed ID: 28273121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation.
    Weyburne ES; Wilkins OM; Sha Z; Williams DA; Pletnev AA; de Bruin G; Overkleeft HS; Goldberg AL; Cole MD; Kisselev AF
    Cell Chem Biol; 2017 Feb; 24(2):218-230. PubMed ID: 28132893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tethered polymer nanoassemblies for sustained carfilzomib release and prolonged suppression of proteasome activity.
    Reichel D; Lee MJ; Lee W; Kim KB; Bae Y
    Ther Deliv; 2016 Oct; 7(10):665-681. PubMed ID: 27790952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity.
    Chen-Scarabelli C; Corsetti G; Pasini E; Dioguardi FS; Sahni G; Narula J; Gavazzoni M; Patel H; Saravolatz L; Knight R; Raddino R; Scarabelli TM
    EBioMedicine; 2017 Jul; 21():206-212. PubMed ID: 28587834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
    Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
    Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.
    Tsakiri EN; Terpos E; Papanagnou ED; Kastritis E; Brieudes V; Halabalaki M; Bagratuni T; Florea BI; Overkleeft HS; Scorrano L; Skaltsounis AL; Dimopoulos MA; Trougakos IP
    Sci Rep; 2017 Dec; 7(1):17802. PubMed ID: 29259189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.